CenterForBiosimilars
3 FOLLOWERS
The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We'll discuss the current landscape for advanced health care management-reviewing emerging treatment paradigms, approaches, and considerations all by authoritative industry voices.
CenterForBiosimilars
6h ago
A review article summarized the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain ..read more
CenterForBiosimilars
23h ago
Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices ..read more
CenterForBiosimilars
23h ago
Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice ..read more
CenterForBiosimilars
1d ago
Here are the top 5 biosimilar articles for the week of April 29, 2024 ..read more
CenterForBiosimilars
2d ago
Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars ..read more
CenterForBiosimilars
3d ago
The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it the second high-concentration adalimumab biosimilar to have an interchangeability designation ..read more
CenterForBiosimilars
3d ago
April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference ..read more
CenterForBiosimilars
4d ago
During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders ..read more
CenterForBiosimilars
5d ago
Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars ..read more
CenterForBiosimilars
5d ago
Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar ..read more